{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:26:22Z","timestamp":1784694382986,"version":"3.55.0"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.2169\/internalmedicine.7623-21","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T22:09:41Z","timestamp":1626473381000},"page":"385-388","source":"Crossref","is-referenced-by-count":4,"title":["Thymic Adenocarcinoma with Positivity for Thyroid Transcription Factor-1 and a BRAF V600E Mutation"],"prefix":"10.2169","volume":"61","author":[{"given":"Takafumi","family":"Yorozuya","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sapporo Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Travis WD, Brambilla E, Burke AP, et al. World Health Organization Classification of Tumors of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2015.","DOI":"10.1097\/JTO.0000000000000663"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 44: 123-130, 2008.","DOI":"10.1016\/j.ejca.2007.11.004"},{"key":"3","unstructured":"3. Ruffini E, Detterbeck F, Raemdonck DV, et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg 46: 361-368, 2014."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S; ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26: v40-v55, 2015.","DOI":"10.1093\/annonc\/mdv277"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kalhor N, Moran CA. Primary thymic adenocarcinomas: a clinicopathological and immunohistochemical study of 16 cases with emphasis on the morphological spectrum differentiation. Hum Pathol 74: 73-82, 2018.","DOI":"10.1016\/j.humpath.2018.01.011"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Koizumi T, Otsuki K, Tanaka Y, et al. National incidence and initial therapy for thymic carcinoma in Japan: based on analysis of hospital-based cancer registry data, 2009-2015. Jpn J Clin Oncol 50: 434-439, 2020.","DOI":"10.1093\/jjco\/hyz203"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kitamura M, Okada H, Miyahara S, et al. Case of primary thymic adenocarcinoma associated with type AB thymoma and thymic cysts. Pathol Int 70: 370-372, 2020.","DOI":"10.1111\/pin.12923"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 364: 2305-2315, 2011.","DOI":"10.1056\/NEJMoa1014209"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14: 455-467, 2014.","DOI":"10.1038\/nrc3760"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jackson MW, Palma DA, Camidge DR, et al. The impact of postoperative radiotherapy for thymoma and thymic carcinoma. J Thorac Oncol 12: 734-744, 2017.","DOI":"10.1016\/j.jtho.2017.01.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hamaji M, Shah RM, Ali SO, Bettenhausen A, Lee HS, Burt BM. A meta-analysis of postoperative radiotherapy for thymic carcinoma. Ann Thorac Surg 103: 1668-1675, 2017.","DOI":"10.1016\/j.athoracsur.2016.12.042"},{"key":"12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2017.03.020","volume":"108","author":"YJ Lim","year":"2017","unstructured":"12. Lim YJ, Song C, Kim JS. Improved survival with postoperative radiotherapy in thymic carcinoma: a propensity-matched analysis of surveillance, epidemiology, and end results (SEER) database. Lung Cancer 108: 161-167, 2017.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by two monoclonal antibodies in pulmonary and non-pulmonary primary tumors. Appl Immunohistochem Mol Morphol 18: 142-149, 2010.","DOI":"10.1097\/PAI.0b013e3181bdf4e7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Conforti F, Tarantino P, Trillo P, et al. Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treat Rev 92: 102133, 2021.","DOI":"10.1016\/j.ctrv.2020.102133"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kawasaki H, Arakaki K, Taira N, et al. Lung cancer detected 5 years after resection of cancer of unknown primary in a mediastinal lymph node: a case report and review of relevant cases from the literature. Ann Thorac Cardiovasc Surg 22: 116-121, 2016.","DOI":"10.5761\/atcs.cr.15-00154"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lee M, Choi SJ, Yoon YH, Kim JT, Baek WK, Kim YS. Metastatic thymic adenocarcinoma from colorectal cancer. Korean J Thorac Cardiovasc Surg 48: 447-451, 2015.","DOI":"10.5090\/kjtcs.2015.48.6.447"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sakane T, Murase T, Okuda K, et al. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A\/B3. Histopathology 75: 755-766, 2019.","DOI":"10.1111\/his.13936"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29: 2060-2065, 2011.","DOI":"10.1200\/JCO.2010.32.9607"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 26: 363-368, 2015.","DOI":"10.1093\/annonc\/mdu541"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Inoue A, Sugawara S, Harada M, et al. Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan lung cancer group study 0803. J Thorac Oncol 9: 1805-1809, 2014.","DOI":"10.1097\/JTO.0000000000000362"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Katsuya Y, Horinouchi H, Seto T, et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 113: 78-86, 2019.","DOI":"10.1016\/j.ejca.2019.03.012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 19: 347-355, 2018.","DOI":"10.1016\/S1470-2045(18)30062-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gbolahan OB, Porter RF, Salter JT, et al. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol 13: 1940-1948, 2018.","DOI":"10.1016\/j.jtho.2018.07.094"},{"key":"24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2019.10.016","volume":"139","author":"Y Tsukita","year":"2020","unstructured":"24. Tsukita Y, Inoue A, Sugawara S, et al. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203. Lung Cancer 139: 89-93, 2020.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med 371: 757-765, 2014.","DOI":"10.1056\/NEJMra1303917"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103, 2012.","DOI":"10.1038\/nature10868"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/3\/61_7623-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T03:15:20Z","timestamp":1644030920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/3\/61_7623-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7623-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"article-number":"7623-21"}}